NCT01858948View on ClinicalTrials.gov

SGA-induced Metabolic Syndrome in Bipolar Youth

PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Bipolar Youth Treated With Second-generation Antipsychotics
Interventions
DRUG

Omega

Omega-3 supplements

DRUG

Placebo

Similar in shape and color to Omega supplements

DRUG

Quetiapine fumarate

Prior to randomization to Omega/placebo, patients were started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.

Trial Locations (1)

45219

University of Cincinnati, Cincinnati

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

University of Cincinnati

OTHER

NCT01858948 - SGA-induced Metabolic Syndrome in Bipolar Youth | Biotech Hunter | Biotech Hunter